Skip to main content

Table 8 Association of PD-L1 staining with estrogen receptor/progesterone receptor-positive and triple-negative status in sTIL subgroups in patients with neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

 

TC

TCIC

IC

sTIL < 10%

sTIL ≥10%

sTIL < 10%

sTIL ≥10%

sTIL < 10%

sTIL ≥10%

PD-L1

Neg

Pos

Neg

Pos

Neg

Pos

Neg

Pos

Neg

Pos

Neg

Pos

ER/PR pos

77

0

13

3

70

2

9

6

70

2

10

5

TNBC

16

3

10

6

11

7

6

8

12

6

9

5

Fisher P value

0.0068

0.4331

0.0001

0.4661

0.0006

1

  1. ER estrogen receptor, PR progesterone receptor, TNBC triple-negative breast cancer, sTIL stromal tumor infiltrating lymphocytes, pos positive, neg negative
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us